Klotho Neuroscience to Acquire Key Assets from Turn Biotechnologies, Secures $300 Million Global Pharma Partnership
Klotho Neurosciences, Inc. has signed a Letter of Intent to acquire key assets from Turn Biotechnologies, including the ERA platform and eTurna RNA delivery system, aimed at regenerative therapies. The deal, involving cash and stock, also includes a $300 million partnership with a South Korean pharmaceutical company, emphasizing the commercial potential of Turn’s technologies. Klotho plans to rebrand and integrate Turn’s management and R&D teams post-transaction.
Klotho Neurosciences, Inc. announced it has signed a Letter of Intent to acquire select assets from Turn Biotechnologies, Inc., a company specializing in induced pluripotent stem cells and cellular reprogramming. The proposed deal, involving both cash and stock, will give Klotho access to Turn’s ERA (Epigenetic Reprogramming of Age) platform and eTurna RNA delivery system. These technologies are designed to rejuvenate somatic cells and support regenerative therapies across a range of conditions, including dermatology, ophthalmology, immunology, osteoarthritis, and neurodegenerative diseases such as ALS. Klotho also revealed plans to rebrand following the transaction and intends to integrate key members of Turn’s management and R&D teams. As part of the deal, Klotho will acquire an existing out-licensing and co-development partnership with a major South Korean pharmaceutical company, valued at up to $300 million. According to Klotho, this partnership highlights the commercial potential of Turn’s platform and supports the company’s expanded mission in longevity therapeutics. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA86133) on September 30, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
